ImmunityBio rises as Anktiva label expansion undergoes FDA review
ImmunityBio, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.24
-3.9% in 1d after detection
Post-detection moves
1h
—
1d
-3.9%
3d
-1.6%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS